Kv Cited by FDA for False Data Firm Also May Lose Right to Sell Two Heart Drugs

By Robert Steyer Of the Post-Dispatch | St Louis Post-Dispatch (MO), December 11, 1994 | Go to article overview
Save to active project

Kv Cited by FDA for False Data Firm Also May Lose Right to Sell Two Heart Drugs


Robert Steyer Of the Post-Dispatch, St Louis Post-Dispatch (MO)


KV Pharmaceutical Co. of Brentwood is one of 19 companies on a special Food and Drug Administration warning list, government documents say.

The FDA, which regulates thousands of medical companies, only puts a firm on the warning list when it is

cited for extreme or repeated cases of providing "false and misleading" data.

"False and misleading information" for some product applications raised "significant questions with regard to the reliability" of KV's test data, says one document explaining why KV has been on the list since April 1993.

Until KV corrects the problems, the FDA has halted scientific review of some drugs submitted by KV for agency approval. The number of drugs is unknown.

KV, which makes timed-release drug technologies and generic drugs, has run afoul of the FDA before.

Twenty months ago, federal agents confiscated many of KV's prescription drugs following a raid on KV's headquarters, some plants and offices in the St. Louis area.

The FDA seized the drugs, charging that KV had failed to follow certain federal regulations covering "good manufacturing practices," including record-keeping and quality control.

Federal documents also say that the FDA is planning to revoke permission for KV to sell two types of prescription heart drugs.

The Post-Dispatch obtained the documents by making a request under the Freedom of Information Act. KV has never told shareholders that it is on the FDA list of companies making "false and misleading" statements.

Calls to KV's chief executive, vice chairman, corporate secretary, director of investor relations and assistant to the director of investor relations were not returned.

When a company seeks FDA approval of a product, it must submit test data showing that the drug is safe and effective. The company also must demonstrate that it can prove that its data is correct.

Companies that fail to meet this requirement can be placed on FDA's Applications Integrity Policy list, whose bureaucratic name doesn't adequately describe problems that FDA has investigated.

This list covers companies that have committed "fraud, untrue statements of material fact, bribery and/or illegal gratuities," the FDA says.

For a company to make the list, the FDA "must establish a pattern or practice of covered misconduct," Brad Williams, director of FDA's division of drug labeling compliance, said in a prepared statement.

"This has usually been falsification of original (product) applications, annual reports, supplements or bribery," he said.

If a company submits bad data, the FDA's response can be as strong as seizing products, ordering a recall or referring the matter to a federal grand jury.

KV landed on the FDA's list just before federal agents staged their raid on April 21, 1993.

"Your firm submitted false or misleading information in applications filed with this agency," says an April 14, 1993 letter to KV from Dr.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Kv Cited by FDA for False Data Firm Also May Lose Right to Sell Two Heart Drugs
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?